{"id":"continuous-doac-therapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding (major and minor)"},{"rate":null,"effect":"Gastrointestinal bleeding"},{"rate":null,"effect":"Intracranial hemorrhage"},{"rate":null,"effect":"Dyspepsia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Direct oral anticoagulants (DOACs) work by inhibiting specific clotting factors (typically Factor Xa or thrombin/Factor IIa) to prevent thrombus formation. Continuous therapy refers to an uninterrupted dosing regimen without scheduled breaks, which may improve efficacy and reduce thrombotic events compared to interrupted dosing patterns in certain clinical scenarios.","oneSentence":"Continuous DOAC therapy maintains uninterrupted anticoagulation using direct oral anticoagulants without treatment gaps.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:07:32.111Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"},{"name":"Venous thromboembolism prevention and treatment"},{"name":"Acute coronary syndrome"}]},"trialDetails":[{"nctId":"NCT05836987","phase":"PHASE3","title":"The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2023-07-13","conditions":"Atrial Fibrillation","enrollment":5350},{"nctId":"NCT05498428","phase":"PHASE2","title":"A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-11-11","conditions":"Carcinoma, Non-small-Cell Lung","enrollment":520},{"nctId":"NCT07005024","phase":"PHASE3","title":"DOAC - Dosing Options in AntiCoagulation Prophylaxis","status":"RECRUITING","sponsor":"University of Vermont","startDate":"2025-10-17","conditions":"Cancer, VTE (Venous Thromboembolism)","enrollment":996},{"nctId":"NCT06195540","phase":"PHASE3","title":"RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing","status":"RECRUITING","sponsor":"University Hospital, Angers","startDate":"2024-07-19","conditions":"Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism","enrollment":1424},{"nctId":"NCT07185295","phase":"PHASE4","title":"Short-term Interruption Versus Continuous Anticoagulation in Colorectal Polypectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Outcomes'10","startDate":"2024-10-18","conditions":"Anticoagulated Patients","enrollment":481},{"nctId":"NCT07208695","phase":"","title":"Effect of Oral Antiplatelet or Anticoagulant Drugs on Postoperative Bleeding Risk and Venous Closure Rate in Patients With Lower Extremity Varicose Veins After Radiofrequency Ablation","status":"NOT_YET_RECRUITING","sponsor":"Chengdu University of Traditional Chinese Medicine","startDate":"2025-10-01","conditions":"Oral Antiplatele, Anticoagulant Drugs, Lower Extremity Varicose Veins","enrollment":40},{"nctId":"NCT06581965","phase":"PHASE4","title":"inDividual, Targeted thrombosIS Prophylaxis Versus the Standard 'One Size Fits All' Approach in Patients Undergoing Total hIp or Total kNee replaCemenT","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2024-11-11","conditions":"Venous Thromboembolism, Venous Thromboses, Pulmonary Embolism","enrollment":10078},{"nctId":"NCT06449469","phase":"NA","title":"The Nordic Aortic Valve Intervention Trial 4 (NOTION-4)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2021-05-01","conditions":"Aortic Valve Stenosis, Cardiovascular Diseases, Heart Diseases","enrollment":352},{"nctId":"NCT06742567","phase":"PHASE3","title":"Apixaban Prophylaxis for Prevention of Left Ventricular Thrombus Following Anterior Myocardial Infarction","status":"RECRUITING","sponsor":"National Institute of Cardiovascular Diseases, Pakistan","startDate":"2024-12-02","conditions":"Acute Myocardial Infarction of Anterior Wall, Left Ventricular Thrombus, Prophylaxis","enrollment":472},{"nctId":"NCT06352632","phase":"PHASE3","title":"ACT-GLOBAL Adaptive Platform Trial for Stroke","status":"RECRUITING","sponsor":"The George Institute","startDate":"2024-09-26","conditions":"Stroke","enrollment":20000},{"nctId":"NCT05419583","phase":"NA","title":"Targeting Investigation and Treatment in Patients With Type 2 Myocardial Infarction","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2022-11-14","conditions":"Myocardial Infarction Type 2","enrollment":60},{"nctId":"NCT05035277","phase":"PHASE3","title":"AntiCoagulation Versus AcetylSalicylic Acid After Transcatheter Aortic Valve Implantation","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2021-12-04","conditions":"Aortic Stenosis","enrollment":360},{"nctId":"NCT02664155","phase":"PHASE3","title":"Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2016-10-19","conditions":"Renal Insufficiency","enrollment":203},{"nctId":"NCT04151680","phase":"","title":"Anticoagulation on Demand After Percutaneous Coronary Intervention in High Bleeding Risk Patients","status":"UNKNOWN","sponsor":"University of Roma La Sapienza","startDate":"2019-12-01","conditions":"Ischemic Heart Disease, Atrial Fibrillation","enrollment":100},{"nctId":"NCT03877848","phase":"","title":"EluNIR Ridaforolimus Eluting Coronary Stent System in Patients at High Bleeding Risk (HBR)- EluNIR HBR Study","status":"COMPLETED","sponsor":"Medinol Ltd.","startDate":"2019-05-06","conditions":"Coronary Stenosis","enrollment":319},{"nctId":"NCT04153201","phase":"NA","title":"Hydroxychloroquine for Thrombosis Prevention and Antiphospholipid Antibody Reduction in Primary Antiphospholipid Syndrome","status":"COMPLETED","sponsor":"National and Kapodistrian University of Athens","startDate":"2013-01-15","conditions":"Antiphospholipid Syndrome","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Oral Anticoagulation therapy"],"phase":"phase_3","status":"active","brandName":"Continuous DOAC therapy","genericName":"Continuous DOAC therapy","companyName":"Johns Hopkins University","companyId":"johns-hopkins-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Continuous DOAC therapy maintains uninterrupted anticoagulation using direct oral anticoagulants without treatment gaps. Used for Atrial fibrillation for stroke prevention, Venous thromboembolism prevention and treatment, Acute coronary syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}